Design Therapeutics Inc (DSGN)

Currency in USD
12.555
-0.085(-0.67%)
Real-time Data·
Trading near 52-week High
DSGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.44012.980
52 wk Range
3.10512.980
Key Statistics
Prev. Close
12.64
Open
12.62
Day's Range
12.44-12.98
52 wk Range
3.105-12.98
Volume
302.11K
Average Vol. (3m)
276.35K
1-Year Change
278.3133%
Book Value / Share
3.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DSGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.667
Upside
+16.82%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Design Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics Inc SWOT Analysis


Future Catalysts
Learn about potential value drivers, including clinical trial results, strategic partnerships, and expansion into new genetic disorder indications
Market Valuation
Analyst price targets range from $4 to $12 per share, reflecting diverse views on Design Therapeutics' potential in the competitive biotech landscape
Pipeline Progress
Delve into the company's lead assets for Friedreich's ataxia and Fuchs corneal dystrophy, and the potential impact on DSGN's market position
GeneTAC Innovation
Explore Design Therapeutics' novel geneTAC platform, combining ASO and small molecule approaches to target genetic disorders with high unmet needs
Read full SWOT analysis

Compare DSGN to Peers and Sector

Metrics to compare
DSGN
Peers
Sector
Relationship
P/E Ratio
−11.2x−5.5x−0.5x
PEG Ratio
0.29−0.120.00
Price / Book
3.7x2.4x2.6x
Price / LTM Sales
-10.8x3.2x
Upside (Analyst Target)
15.2%45.8%47.6%
Fair Value Upside
Unlock−2.9%6.1%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.667
(+16.82% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy15.00+19.05%-New CoverageMar 16, 2026
RBC Capital
Buy14.00+11.11%13.00MaintainMar 10, 2026
Piper Sandler
Buy12.00-4.76%-MaintainMar 10, 2026
Oppenheimer
Buy18.00+42.86%-New CoverageJan 07, 2026
Craig-Hallum
Buy15.00+19.05%-New CoverageDec 03, 2025

Earnings

Latest Release
Mar 09, 2026
EPS / Forecast
-0.27 / -0.33
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

DSGN Income Statement

People Also Watch

20.88
ZBIO
-2.18%
65.77
LASR
-1.65%
10.6650
ADMA
+1.67%
27.62
RHI
+8.83%
18.075
AMPX
+1.03%

FAQ

What Is the Design Therapeutics (DSGN) Stock Price Today?

The Design Therapeutics stock price today is 12.555 USD.

What Stock Exchange Does Design Therapeutics Trade On?

Design Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Design Therapeutics?

The stock symbol for Design Therapeutics is "DSGN."

What Is the Design Therapeutics Market Cap?

As of today, Design Therapeutics market cap is 777.070M USD.

What Is Design Therapeutics's Earnings Per Share (TTM)?

The Design Therapeutics EPS (TTM) is -1.217.

When Is the Next Design Therapeutics Earnings Date?

Design Therapeutics will release its next earnings report on May 11, 2026.

From a Technical Analysis Perspective, Is DSGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Design Therapeutics Stock Split?

Design Therapeutics has split 0 times.

How Many Employees Does Design Therapeutics Have?

Design Therapeutics has 54 employees.

What is the current trading status of Design Therapeutics (DSGN)?

As of Apr 15, 2026, Design Therapeutics (DSGN) is trading at a price of 12.555 USD, with a previous close of 12.640 USD. The stock has fluctuated within a day range of 12.440 USD to 12.980 USD, while its 52-week range spans from 3.105 USD to 12.980 USD.

What Is Design Therapeutics (DSGN) Price Target According to Analysts?

The average 12-month price target for Design Therapeutics is 14.667 USD, with a high estimate of 18 USD and a low estimate of 12 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +16.82% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.